EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings

Rodica Stan iD, Richa Madan Lomash, Oleg A Shchelochkov, Irini Manoli, Carolina I Galarreta Aima, Venkata Mangalampalli, Eun-Young Choi, Randy J Chandler, Lina Li, Jennifer L Sloan, Pramod Terse, Xin Xu und 6 weitere

Human Gene Therapy · 2026

DOI: 10.1177/10430342261452217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Rodica Stan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutic Development Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland, U…. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors, Rare Diseases. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Platform Vector-Gene Therapy (PaVe-GT) program is a National Institutes of Health (NIH) initiative that aims to develop adeno-associated virus (AAV) gene therapies for four monogenic rare diseases, two organic acidemias and two congenital myasthenic syndromes. PaVe-GT’s platform-based approach identifies and diminishes redundancies and applies efficiencies in preclinical, clinical, and regulatory activities. The program’s hypothesis is that implementing these efficiencies can accelerate clinical trial initiation. Based on its platform-centric experience and public-serving mission, the PaVe-GT program actively shares its scientific and regulatory learnings with the public to benefit the development of similar gene therapy products for rare diseases. PaVe-GT’s first investigational AAV gene therapy candidate is AAV serotype 9 human propionyl-CoA carboxylase alpha subunit (AAV9-hPCCA) for propionic acidemia caused by PCCA deficiency, which received initial feedback from the Food and Drug Administration (FDA) in an IN itial T argeted E ngagement for R egulatory A dvice on C BER/Center for Drug Evaluation and Research (CDER) Produc T s (INTERACT) meeting. Upon further product development that took into consideration the FDA’s initial advice, the program obtained the Agency’s feedback in pre-investigational new drug (IND) (Type B) and Type C meetings. Here, we share our experience from these meetings, including strategy, preparation, pre- and post-meeting feedback from the FDA, and lessons learned during the AAV9-hPCCA regulatory process, which the program plans to apply across the PaVe-GT platform. Topics discussed in the regulatory meetings included animal model and efficacy studies, toxicology study plans, manufacturing of the investigational AAV product, and clinical trial design. The main lessons learned from the pre-IND and Type C meetings for AAV9-hPCCA are: (1) Pharmacology/Toxicology studies in a single rodent species are sufficient for filing an initial IND; (2) FDA feedback guides product quality improvements and early development of a quantitative potency assay; (3) use of biomarkers as potential surrogate endpoints in a future efficacy trial benefits from collection of data in the natural history study and the first-in-human Phase 1/2 study; and (4) evidence from the Phase 1/2 clinical trial could be leveraged to support a license application. Lightly redacted regulatory documents and comprehensive templates developed by the PaVe-GT team are available on the PaVe-GT website.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyGenetic VectorsRare DiseasesHumansUnited StatesGene Therapy AgentsAnimalsUnited States Food and Drug AdministrationTranslational Research, BiomedicalClinical Trials as Topic

Stichwörter der Autor:innen

AAV9FDA type B meetingFDA type C meetingPCCAPaVe-GTgene therapypre-IND meetingpropionic acidemiarare diseases

Autor:innen und Institutionen

  • Therapeutic Development Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland, USA.
  • Organic Acid Research Section, Metabolic Medicine Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
  • Division of Rare Diseases Research and Innovation, NCATS, NIH, Rockville, Maryland, USA.
  • Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.

ORCID-Profile: Rodica Stan

Zitieren

APA

Stan, R., Lomash, R. M., Shchelochkov, O. A., Manoli, I., Galarreta Aima, C. I., Mangalampalli, V., Choi, E. Y., Chandler, R. J., Li, L., Sloan, J. L., Terse, P., Xu, X., PaVe-GT Team, Dehdashti, J., Brooks, P. J., Bönnemann, C. G., Venditti, C. P., & Ottinger, E. A. (2026). Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings. Human Gene Therapy. https://doi.org/10.1177/10430342261452217

Vancouver

Stan R, Lomash RM, Shchelochkov OA, Manoli I, Galarreta Aima CI, Mangalampalli V, et al. Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings. Human Gene Therapy. 2026. doi:10.1177/10430342261452217

BibTeX
@article{Stan2026,
  author = {Stan, Rodica and Lomash, Richa Madan and Shchelochkov, Oleg A and Manoli, Irini and Galarreta Aima, Carolina I and Mangalampalli, Venkata and Choi, Eun-Young and Chandler, Randy J and Li, Lina and Sloan, Jennifer L and Terse, Pramod and Xu, Xin and PaVe-GT Team, PaVe-GT Team and Dehdashti, Jean and Brooks, Philip J and Bönnemann, Carsten G and Venditti, Charles P and Ottinger, Elizabeth A},
  title = {Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261452217}
}
Kostenlos starten →